Molecular mechanisms of ETS transcription factor-mediated tumorigenesis

Critical Reviews in Biochemistry and Molecular Biology

Volumn 48, Issue 6, 2013, Pages 522-543

  Kar, Adwitiya ^a   Gutierrez Hartmann, Arthur ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

ETS; ETS activator repressor switch; ETS fusion; ETS in stroma; ETS in tumorigenesis; ETS overexpression; ETS post translational modifications; ETS tumorigenic mechanism

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETS DBD PROTEIN; EWS ERG PROTEIN; EWS FLI PROTEIN; GA BINDING PROTEIN; HYBRID PROTEIN; INHIBITOR OF DIFFERENTIATION PROTEIN; MASPIN; MATRILYSIN; PROTEIN BCL 2; PROTEIN C FOS; SCATTER FACTOR RECEPTOR; SURVIVIN; TRANSCRIPTION FACTOR ELF 1; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR ETS 2; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR PEA3; TRANSCRIPTION FACTOR PU 1; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; VASCULOTROPIN C;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ANGIOMA; BINDING SITE; BREAST CARCINOMA; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILDHOOD CANCER; CLONOGENESIS; COLORECTAL CARCINOMA; CONFORMATIONAL TRANSITION; DIMERIZATION; DNA BINDING; DNA PROTEIN COMPLEX; DNA SEQUENCE; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; ERYTHROLEUKEMIA; EWING SARCOMA; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; INVASIVE CARCINOMA; LYMPHATIC LEUKEMIA; MENINGIOMA; MULTIGENE FAMILY; NONHUMAN; OLIGOMERIZATION; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PHYLOGENY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROTEIN DNA BINDING; PROTEIN DNA INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; PROTEIN STABILITY; RETINOBLASTOMA; REVIEW; T LYMPHOCYTE ACTIVATION; THYMOMA; THYROID CARCINOMA; TRANSCRIPTION INITIATION; WNT SIGNALING PATHWAY;

APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-ETS; SIGNAL TRANSDUCTION;

EID: 84888585803     PISSN: 10409238     EISSN: 15497798     Source Type: Journal    
DOI: 10.3109/10409238.2013.838202     Document Type: Review

References (238)

1. Abaan OD, Levenson A, Khan O, et al. (2005). PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis. Oncogene 24:2715-22. (Pubitemid 40593099)
2. Agarkar VB, Babayeva ND, Wilder PJ, et al. (2010). Crystal structure of mouse Elf3 C-terminal DNA-binding domain in complex with type II TGF-beta receptor promoter DNA. J Mol Biol 397:278-89.
3. Albino D, Longoni N, Curti L, et al. (2012). ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features. Cancer Res 72:2889-900.
4. Alipov G, Nakayama T, Ito M, et al. (2005). Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas. Histopathology 46:202-8. (Pubitemid 40293019)
5. Alvarez-Erviti L, Seow Y, Yin H, et al. (2011). Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29:341-5.
6. Anderson JL, Denny CT, Tap WD, Federman N. (2012). Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities. Pediatr Res 72:112-21.
7. Aryee DN, Niedan S, Kauer M, et al. (2010). Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro. Cancer Res 70:4015-23.
8. Augustijn KD, Duval DL, Wechselberger R, et al. (2002). Structural characterization of the PIT-1/ETS-1 interaction: PIT-1 phosphoryl-ation regulates PIT-1/ETS-1 binding. Proc Natl Acad Sci USA 99: 12657-62.
9. Baert JL, Beaudoin C, Coutte L, De launoit Y. (2002). ERM transactivation is up-regulated by the repression of DNA binding after the PKA phosphorylation of a consensus site at the edge of the ETS domain. J Biol Chem 277:1002-12. (Pubitemid 34968845)
10. Baker KM, Wei G, Schaffner AE, Ostrowski MC. (2003). Ets-2 and components of mammalian SWI/SNF form a repressor complex that negatively regulates the BRCA1 promoter. J Biol Chem 278: 17876-84. (Pubitemid 36799393)
11. Baldus CD, Liyanarachchi S, Mrozek K, et al. (2004). Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: amplification discloses overexpression of APP, ETS2, and ERG genes. Proc Natl Acad Sci USA 101:3915-20. (Pubitemid 38381077)
12. Ban J, Jug G, Mestdagh P, et al. (2011). Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma. Oncogene 30:2173-80.
13. Barski A, Zhao K. (2009). Genomic location analysis by ChIP-Seq. J Cell Biochem 107:11-18.
14. Bartfeld D, Shimon L, Couture GC, et al. (2002). DNA recognition by the RUNX1 transcription factor is mediated by an allosteric transition in the RUNT domain and by DNA bending. Structure 10:1395-407. (Pubitemid 35232385)
15. Bassuk AG, Anandappa RT, Leiden JM. (1997). Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells. J Virol 71:3563-73. (Pubitemid 27172366)
16. Beauchamp E, Bulut G, Abaan O, et al. (2009). GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem 284: 9074-82.
17. Behrens P, Mathiak M, Mangold E, et al. (2003). Stromal expression of invasion-promoting, matrix-degrading proteases MMP-1 and-9 and the Ets 1 transcription factor in HNPCC carcinomas and sporadic colorectal cancers. Int J Cancer 107:183-8. (Pubitemid 37152895)
18. Behrens P, Rothe M, Wellmann A, et al. (2001). The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. J Pathol 194:43-50.
19. Benz CC, O'Hagan RC, Richter B, et al. (1997). HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 15:1513-25. (Pubitemid 27464644)
20. Bieche I, Tozlu S, Girault I, et al. (2004). Expression of PEA3/E1AF/ETV4, an Ets-related transcription factor, in breast tumors: positive links to MMP2, NRG1 and CGB expression. Carcinogenesis 25:405-11. (Pubitemid 38351094)
21. Bosc DG, Goueli BS, Janknecht R. (2001). HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1. Oncogene 20:6215-24. (Pubitemid 32964434)
22. Bosselut R, Levin J, Adjadj E, Ghysdael J. (1993). A single amino-acid substitution in the Ets domain alters core DNA binding specificity of Ets1 to that of the related transcription factors Elf1 and E74. Nucleic Acids Res 21:5184-91. (Pubitemid 23342531)
23. Brass AL, Kehrli E, Eisenbeis CF, et al. (1996). Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1. Genes Dev 10:2335-47. (Pubitemid 26322369)
24. Buijs A, Van Rompaey L, Molijn AC, et al. (2000). The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity. Mol Cell Biol 20:9281-93. (Pubitemid 32246113)
25. Burda P, Curik N, Kokavec J, et al. (2009). PU.1 activation relieves GATA-1-mediated repression of Cebpa and Cbfb during leukemia differentiation. Mol Cancer Res 7:1693-703.
26. Cangemi R, Mensah A, Albertini V, et al. (2008). Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer. Oncogene 27:2877-85. (Pubitemid 351620453)
27. Chae H, Kim M, Lim J, et al. (2010). B lymphoblastic leukemia with ETV6 amplification. Cancer Genet Cytogenet 203:284-7.
28. Chakrabarti SR, Nucifora G. (1999). The leukemia-associated gene TEL encodes a transcription repressor which associates with SMRT and mSin3A. Biochem Biophys Res Commun 264:871-7.
29. Chakrabarti SR, Sood R, Ganguly S, et al. (1999). Modulation of TEL transcription activity by interaction with the ubiquitin-conjugating enzyme UBC9. Proc Natl Acad Sci USA 96: 7467-72. (Pubitemid 29299685)
30. Chakrabarti SR, Sood R, Nandi S, Nucifora G. (2000). Posttranslational modification of TEL and TEL/AML1 by SUMO-1 and cell-cycle-dependent assembly into nuclear bodies. Proc Natl Acad Sci USA 97: 13281-5.
31. Chen A, Xu J, Johnson AC. (2006). Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 25:278-87. (Pubitemid 43083689)
32. Cowley DO, Graves BJ. (2000). Phosphorylation represses Ets-1 DNA binding by reinforcing autoinhibition. Genes Dev 14: 366-76. (Pubitemid 30106491)
33. Crawford HC, Fingleton B, Gustavson MD, et al. (2001). The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors. Mol Cell Biol 21:1370-83. (Pubitemid 32114984)
34. Czuwara-Ladykowska J, Sementchenko VI, Watson DK, Trojanowska M. (2002). Ets1 is an effector of the transforming growth factor beta (TGF-beta) signaling pathway and an antagonist of the profibrotic effects of TGF-beta. J Biol Chem 277:20399-408. (Pubitemid 34967335)
35. De Braekeleer E, Douet-Guilbert N, Morel F, et al. (2012). ETV6 fusion genes in hematological malignancies: a review. Leuk Res 36: 945-61.
36. de Launoit Y, Chotteau-Lelievre A, Beaudoin C, et al. (2000). The PEA3 group of ETS-related transcription factors. Role in breast cancer metastasis. Adv Exp Med Biol 480:107-16. (Pubitemid 32176100)
37. De Vito C, Riggi N, Suva ML, et al. (2011). Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development. PLoS One 6:10.
38. Delannoy-Courdent A, Mattot V, Fafeur V, et al. (1998). The expression of an Ets1 transcription factor lacking its activation domain decreases uPA proteolytic activity and cell motility, and impairs normal tubulogenesis and cancerous scattering in mammary epithelial cells. J Cell Sci 111:1521-34. (Pubitemid 28288824)
39. Deneen B, Denny CT. (2001). Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene 20:6731-41. (Pubitemid 33020602)
40. Diakos C, Zhong S, Xiao Y, et al. (2010). TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and miRNA-320a. Blood 116: 4885-93.
41. Dittmer J. (2003). The biology of the Ets1 proto-oncogene. Mol Cancer 2:29-49.
42. Dittmer J, Vetter M, Blumenthal SG, et al. (2004). Importance of ets1 proto-oncogene for breast cancer progression. Zentralbl Gynakol 126:269-71. (Pubitemid 39209172)
43. Donaldson LW, Petersen JM, Graves BJ, Mcintosh LP. (1996). Solution structure of the ETS domain from murine Ets-1: a winged helix-turn-helix DNA binding motif. Embo J 15:125-34. (Pubitemid 26020395)
44. Eckel KL, Tentler JJ, Cappetta GJ, et al. (2003). The epithelial-specific ETS transcription factor ESX/ESE-1/Elf-3 modulates breast cancer-associated gene expression. DNA Cell Biol 22:79-94. (Pubitemid 36408138)
45. Eguchi M, Eguchi-Ishimae M, Tojo A, et al. (1999). Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood 93:1355-63. (Pubitemid 29076151)
46. Elvert G, Kappel A, Heidenreich R, et al. (2003). Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J Biol Chem 278:7520-30. (Pubitemid 36800759)
47. Erkizan HV, Uversky VN, Toretsky JA. (2010). Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma. Clin Cancer Res 16:4077-83.
48. Farnham PJ. (2009). Insights from genomic profiling of transcription factors. Nat Rev Genet 10:605-16.
49. Feldman RJ, Sementchenko VI, Watson DK. (2003). The epithelial-specific Ets factors occupy a unique position in defining epithelial proliferation, differentiation and carcinogenesis. Anticancer Res 23: 2125-31. (Pubitemid 36897172)
50. Firlej V, Ladam F, Brysbaert G, et al. (2008). Reduced tumorigenesis in mouse mammary cancer cells following inhibition of Pea3-or Erm-dependent transcription. J Cell Sci 121:3393-402.
51. Fitzsimmons D, Lukin K, Lutz R, et al. (2009). Highly cooperative recruitment of Ets-1 and release of autoinhibition by Pax5. J Mol Biol 392:452-64.
52. Fleming FJ, Myers E, Kelly G, et al. (2004). Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J Clin Pathol 57:1069-74. (Pubitemid 39331358)
53. Ford AM, Palmi C, Bueno C, et al. (2009). The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. J Clin Invest 119:826-36.
54. Foulds CE, Nelson ML, Blaszczak AG, Graves BJ. (2004). Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment. Mol Cell Biol 24:10954-64. (Pubitemid 39603149)
55. Fuchs B, Inwards CY, Janknecht R. (2003). Upregulation of the matrix metalloproteinase-1 gene by the Ewing's sarcoma associated EWS-ER81 and EWS-Fli-1 oncoproteins, c-Jun and p300. FEBS Lett 553:104-8. (Pubitemid 37206333)
56. Fukuma M, Okita H, Hata J, Umezawa A. (2003). Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma. Oncogene 22:1-9. (Pubitemid 36152878)
57. Galang CK, Muller WJ, Foos G, et al. (2004). Changes in the expression of many Ets family transcription factors and of potential target genes in normal mammary tissue and tumors. J Biol Chem 279:11281-92. (Pubitemid 38401625)
58. Gangwal K, Sankar S, Hollenhorst PC, et al. (2008). Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proc Natl Acad Sci USA 105:10149-54.
59. Garcia-aragoncillo E, Carrillo J, Lalli E, et al. (2008). DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells. Oncogene 27:6034-43.
60. Garvie CW, Hagman J, Wolberger C. (2001). Structural studies of Ets-1/Pax5 complex formation on DNA. Mol Cell 8:1267-76. (Pubitemid 34084998)
61. Garvie CW, Pufall MA, Graves BJ, Wolberger C. (2002). Structural analysis of the autoinhibition of Ets-1 and its role in protein partnerships. J Biol Chem 277:45529-36. (Pubitemid 36159163)
62. Gavrilov, D., Kenzior, O., Evans, M., et al. (2001). Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. Eur J Cancer 37:1033-40. (Pubitemid 32397690)
63. Ge Y, Lafiura KM, Dombkowski AA, et al. (2008). The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. Leukemia 22:521-9. (Pubitemid 351386721)
64. Ghosh S, Basu M, Roy SS. (2012). ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3. J Biol Chem 287:15001-15.
65. Gilles C, Polette M, Birembaut P, et al. (1997). Expression of c-ets-1 mRNA is associated with an invasive, EMT-derived phenotype in breast carcinoma cell lines. Clin Exp Metastasis 15:519-26. (Pubitemid 27323901)
66. Giovane A, Pintzas A, Maira SM, et al. (1994). Net, a new ets transcription factor that is activated by Ras. Genes Dev 8:1502-13. (Pubitemid 24218285)
67. Goel A, Janknecht R. (2003). Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF, and HER2/Neu. Mol Cell Biol 23:6243-54. (Pubitemid 37013101)
68. Goetz TL, Gu TL, Speck NA, Graves BJ. (2000). Auto-inhibition of Ets-1 is counteracted by DNA binding cooperativity with core-binding factor alpha2. Mol Cell Biol 20:81-90. (Pubitemid 30002550)
69. Golub TR, Barker GF, Lovett M, Gilliland DG. (1994). Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307-16. (Pubitemid 24138627)
70. Golub TR, Goga A, Barker GF, et al. (1996). Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 16:4107-16. (Pubitemid 26251210)
71. Graves BJ, Cowley DO, Goetz TL, et al. (1998). Autoinhibition as a transcriptional regulatory mechanism. Cold Spring Harb Symp Quant Biol 63:621-9. (Pubitemid 29282207)
72. Greenall A, Willingham N, Cheung E, et al. (2001). DNA binding by the ETS-domain transcription factor PEA3 is regulated by intramolecular and intermolecular protein.protein interactions. J Biol Chem 276: 16207-15.
73. Gu S, Chen L, Hong Q, et al. (2011). PEA3 activates CXCR4 transcription in MDA-MB-231 and MCF7 breast cancer cells. Acta Biochim Biophys Sin 43:771-8.
74. Gu TL, Goetz TL, Graves BJ, Speck NA. (2000). Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1). Mol Cell Biol 20: 91-103. (Pubitemid 30002551)
75. Gu X, Zerbini LF, Otu HH, et al. (2007). Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res 67:4219-26. (Pubitemid 46815068)
76. Guidez F, Petrie K, Ford AM, et al. (2000). Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein. Blood 96:2557-61.
77. Gutierrez-Hartmann A, Duval DL, Bradford AP. (2007). ETS transcription factors in endocrine systems. Trends Endocrinol Metab 18:150-8. (Pubitemid 46629025)
78. Hagman J, Grosschedl R. (1992). An inhibitory carboxyl-terminal domain in Ets-1 and Ets-2 mediates differential binding of ETS family factors to promoter sequences of the mb-1 gene. Proc Natl Acad Sci USA 89:8889-93.
79. Hamalainen M, Juvonen V, Haikio S, et al. (2010). ETS-related gene ERG expression in AML patients is significantly associated with NPM1 mutation status. Eur J Haematol 85:361-2.
80. Heidenreich O, Krauter J, Riehle H, et al. (2003). AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood 101: 3157-63. (Pubitemid 36858010)
81. Hermkens MC, Van Den Heuvel-Eibrink MM, Arentsen-Peters ST, et al. (2013). The clinical relevance of BAALC and ERG expression levels in pediatric AML. Leukemia 27:735-7.
82. Hiebert SW, Sun W, Davis JN, et al. (1996). The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol 16:1349-55. (Pubitemid 26095605)
83. Hollenhorst PC, Chandler KJ, Poulsen RL, et al. (2009). DNA specificity determinants associate with distinct transcription factor functions. PLoS Genet 5:e1000778.
84. Hollenhorst PC, Ferris MW, Hull MA, et al. (2011a). Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev 25:2147-57.
85. Hollenhorst PC, Jones DA, Graves BJ. (2004). Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res 32:5693-702. (Pubitemid 39545685)
86. Hollenhorst PC, Mcintosh LP, Graves BJ. (2011b). Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem 80:437-71.
87. Hollenhorst PC, Shah AA, Hopkins C, Graves BJ. (2007). Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev 21:1882-94. (Pubitemid 47204928)
88. Horn S, Figl A, Rachakonda PS, et al. (2013). TERT promoter mutations in familial and sporadic melanoma. Science 339:959-61.
89. Hsu T, Trojanowska M, Watson DK. (2004). Ets proteins in biological control and cancer. J Cell Biochem 91:896-903.
90. Hu Z, Gu X, Baraoidan K, et al. (2011). RUNX1 regulates corepressor interactions of PU.1. Blood 117:6498-508.
91. Hua D, Chen B, Bai M, et al. (2009). PEA3 activates VEGF transcription in T47D and SKBR3 breast cancer cells. Acta Biochim Biophys Sin 41:63-8.
92. Huang FW, Hodis E, Xu MJ, et al. (2013). Highly recurrent TERT promoter mutations in human melanoma. Science 339:957-9.
93. Huang HY, Illei PB, Zhao Z, et al. (2005). Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 23:548-58. (Pubitemid 46224232)
94. Ito T, Nakayama T, Ito M, et al. (1998). Expression of the ets-1 proto-oncogene in human pancreatic carcinoma. Mod Pathol 11:209-15. (Pubitemid 28144158)
95. Ito Y, Takeda T, Okada M, Matsuura N. (2002). Expression of ets-1 and ets-2 in colonic neoplasms. Anticancer Res 22:1581-4. (Pubitemid 34839167)
96. Janknecht R. (2001). Cell type-specific inhibition of the ETS transcription factor ER81 by mitogen-activated protein kinase-activated protein kinase 2. J Biol Chem 276:41856-61.
97. Janknecht R. (2003). Regulation of the ER81 transcription factor and its coactivators by mitogen-and stress-activated protein kinase 1 (MSK1). Oncogene 22:746-55. (Pubitemid 36269288)
98. Jedlicka P, Sui X, Gutierrez-Hartmann A. (2009). The Ets dominant repressor En/Erm enhances intestinal epithelial tumorigenesis in ApcMin mice. BMC Canc 9:1471-2407.
99. Jiang Y, Xu W, Lu J, et al. (2001). Invasiveness of hepatocellular carcinoma cell lines: contribution of hepatocyte growth factor, c-met, and transcription factor Ets-1. Biochem Biophys Res Commun 286: 1123-30. (Pubitemid 32924886)
100. Juang YT, Solomou EE, Rellahan B, Tsokos GC. (2002). Phosphorylation and O-linked glycosylation of Elf-1 leads to its translocation to the nucleus and binding to the promoter of the TCR zeta-chain. J Immunol 168:2865-71. (Pubitemid 34211666)
101. Kalyuga M, Gallego-Ortega D, Lee HJ, et al. (2012). ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer. PLoS Biol 10:27.
102. Kamesaki H, Nishizawa K, Michaud GY, et al. (1998). TGF-beta 1 induces the cyclin-dependent kinase inhibitor p27Kip1 mRNA and protein in murine B cells. J Immunol 160:770-7. (Pubitemid 28049318)
103. Kawagoe H, Grosveld GC. (2005). MN1-TEL myeloid oncoprotein expressed in multipotent progenitors perturbs both myeloid and lymphoid growth and causes T-lymphoid tumors in mice. Blood 106: 4278-86. (Pubitemid 41775937)
104. Killela PJ, Reitman ZJ, Jiao Y, et al. (2013). TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110:6021-6.
105. Kim CA, Phillips ML, Kim W, et al. (2001). Polymerization of the SAM domain of TEL in leukemogenesis and transcriptional repression. EMBO J 20:4173-82. (Pubitemid 32751833)
106. Kim S, Denny CT, Wisdom R. (2006). Cooperative DNA binding with AP-1 proteins is required for transformation by EWS-Ets fusion proteins. Mol Cell Biol 26:2467-78.
107. Kim WY, Sieweke M, Ogawa E, et al. (1999). Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains. EMBO J 18:1609-20. (Pubitemid 29127073)
108. Kinsey M, Smith R, Iyer AK, et al. (2009). EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and onco-genesis in Ewing's sarcoma. Cancer Res 69:9047-55.
109. Kitange G, Tsunoda K, Anda T, et al. (2000). Immunohistochemical expression of Ets-1 transcription factor and the urokinase-type plasminogen activator is correlated with the malignant and invasive potential in meningiomas. Cancer 89:2292-300.
110. Knezevich SR, Mcfadden DE, Tao W, et al. (1998). A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 18:184-7. (Pubitemid 28082471)
111. Knoop LL, Baker SJ. (2000). The splicing factor U1C represses EWS/FLI-mediated transactivation. J Biol Chem 275:24865-71. (Pubitemid 30626591)
112. Knowles HJ, Schaefer KL, Dirksen U, Athanasou NA. (2010). Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of hypoxia-inducible factor. BMC Cancer 10: 372.
113. Kovar H. (2012). The first European Interdisciplinary Ewing Sarcoma Research Summit. Front Oncol 2:2-10.
114. Lacronique V, Boureux A, Valle VD, et al. (1997). A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278:1309-12. (Pubitemid 27495745)
115. Latinkic BV, Zeremski M, Lau LF. (1996). Elk-1 can recruit srf to form a ternary complex upon the serum response element. Nucl Acid Res 24:1345-51.
116. Lee GM, Donaldson LW, Pufall MA, et al. (2005). The structural and dynamic basis of Ets-1 DNA binding autoinhibition. J Biol Chem 280: 7088-99. (Pubitemid 40341265)
117. Lee HJ, Ormandy CJ. (2012). Elf5, hormones and cell fate. Trends Endocrinol Metab 23:292-8.
118. Lee S-H. (2005). The HPV-18 E7 oncoprotein binds Elk-1 and regulates its transcriptional activity. AACR Meet Abstr 2005:1286-a-.
119. Lessnick SL, Dacwag CS, Golub TR. (2002). The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 1:393-401. (Pubitemid 41039140)
120. Li B, Shimizu Y, Kobayashi T, et al. (2012b). Overexpression of ETS-1 is associated with malignant biological features of prostate cancer. Asian J Androl 14:860-3.
121. Li QJ, Yang SH, Maeda Y, et al. (2003). MAP kinase phosphorylation- dependent activation of Elk-1 leads to activation of the co-activator p300. Embo J 22:281-91. (Pubitemid 36119434)
122. Li R, Pei H, Watson DK. (2000). Regulation of Ets function by protein-protein interactions. Oncogene 19:6514-23. (Pubitemid 32108441)
123. Li Y, Li X, Fan G, et al. (2012a). Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors. Cancer Lett 320: 14-22.
124. Lopez RG, Carron C, Oury C, et al. (1999). TEL is a sequence-specific transcriptional repressor. J Biol Chem 274:30132-8.
125. Luo W, Gangwal K, Sankar S, et al. (2009). GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance. Oncogene 28:4126-32.
126. Maki K, Arai H, Waga K, et al. (2004). Leukemia-related transcription factor TEL is negatively regulated through extracellular signal-regulated kinase-induced phosphorylation. Mol Cell Biol 24:3227-37. (Pubitemid 38452068)
127. Man AK, Young LJ, Tynan JA, et al. (2003). Ets2-dependent stromal regulation of mouse mammary tumors. Mol Cell Biol 23:8614-25. (Pubitemid 37433366)
128. Manavathi B, Rayala SK, Kumar R. (2007). Phosphorylation-dependent regulation of stability and transforming potential of ETS transcrip-tional factor ESE-1 by p21-activated kinase 1. J Biol Chem 282: 19820-30. (Pubitemid 47100123)
129. Marcucci G, Baldus CD, Ruppert AS, et al. (2005). Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 23:9234-42.
130. Massague J, Blain SW, Lo RS. (2000). TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103:295-309.
131. Massie CE, Adryan B, Barbosa-Morais NL, et al. (2007). New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 8:871-8. (Pubitemid 350001432)
132. Matsumura I, Kitamura T, Wakao H, et al. (1999). Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. Embo J 18: 1367-77. (Pubitemid 29110320)
133. Mavrothalassitis G, Ghysdael J. (2000). Proteins of the ETS family with transcriptional repressor activity. Oncogene 19:6524-32. (Pubitemid 32108442)
134. Mckinsey EL, Parrish JK, Irwin AE, et al. (2011). A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. Oncogene 30:4910-20.
135. Meyers S, Lenny N, Hiebert SW. (1995). The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol 15:1974-82.
136. Mishra L, Derynck R, Mishra B. (2005). Transforming growth factor-beta signaling in stem cells and cancer. Science 310:68-71. (Pubitemid 41434534)
137. Mo Y, Vaessen B, Johnston K, Marmorstein R. (1998). Structures of SAP-1 bound to DNA targets from the E74 and c-fos promoters: insights into DNA sequence discrimination by Ets proteins. Mol Cell 2:201-12. (Pubitemid 128373645)
138. Mo Y, Vaessen B, Johnston K, Marmorstein R. (2000). Structure of the elk-1-DNA complex reveals how DNA-distal residues affect ETS domain recognition of DNA. Nat Struct Biol 7:292-7. (Pubitemid 30194452)
139. Mochmann LH, Bock J, Ortiz-Tanchez J, et al. (2011). Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG. Oncogene 30:2044-56.
140. Naito S, Shimizu K, Nakashima M, et al. (2000). Overexpression of Ets-1 transcription factor in angiosarcoma of the skin. Pathol Res Pract 196:103-9. (Pubitemid 30095645)
141. Nakayama T, Ito M, Ohtsuru A, et al. (1999). Expression of the ets-1 proto-oncogene in human thyroid tumor. Mod Pathol 12:61-8. (Pubitemid 29059168)
142. Nakayama T, Ito M, Ohtsuru A, et al. (2001). Expression of the ets-1 proto-oncogene in human colorectal carcinoma. Mod Pathol 14:415-22. (Pubitemid 32448739)
143. Nelson ML, Kang HS, Lee GM, et al. (2010). Ras signaling requires dynamic properties of Ets1 for phosphorylation-enhanced binding to coactivator CBP. Proc Natl Acad Sci USA 107:10026-31.
144. Nelson ML, Kang HS, Lee GM, et al. (2010). Ras signaling requires dynamic properties of Ets1 for phosphorylation-enhanced binding to coactivator CBP. Proc Natl Acad Sci USA 107:10026-31.
145. Neznanov N, Man AK, Yamamoto H, et al. (1999). A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice. Cancer Res 59:4242-6. (Pubitemid 29418736)
146. Ng KP, Potikyan G, Savene RO, et al. (2007). Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteins. Proc Natl Acad Sci USA 104:479-84. (Pubitemid 46123051)
147. Nosaka T, Kawashima T, Misawa K, et al. (1999). STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoi-etic cells. Embo J, 18:4754-65. (Pubitemid 29415529)
148. O'Brien P, Morin Jr P, Ouellette RJ, Robichaud GA. (2011). The Pax-5 gene: a pluripotent regulator of B-cell differentiation and cancer disease. Cancer Res 71:7345-50.
149. O'Hagan RC, Hassell JA. (1998). The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase. Oncogene 16:301-10. (Pubitemid 28052284)
150. Oettgen P, Finger E, Sun Z, et al. (2000). PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the andro-gen receptor and activates prostate-specific antigen gene expression. J Biol Chem 275:1216-25. (Pubitemid 30051174)
151. Oikawa T, Yamada T. (2003). Molecular biology of the Ets family of transcription factors. Gene 303:11-34. (Pubitemid 36151767)
152. Okuducu AF, Zils U, Michaelis SA, et al. (2006). Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9. Cancer 107:1365-72. (Pubitemid 44452787)
153. Otsubo K, Kanegane H, Eguchi M, et al. (2010). ETV6-ARNT fusion in a patient with childhood T lymphoblastic leukemia. Cancer Genet Cytogenet 202:22-6.
154. Papadopoulos P, Ridge SA, Boucher CA, et al. (1995). The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res 55:34-8.
155. Papas TS, Watson DK, Sacchi N, et al. (1986). Molecular evolution of ets genes from avians to mammals and their cytogenetic localization to regions involved in leukemia. Gene Amplif Anal 4:207-38.
156. Park S, Chen W, Cierpicki T, et al. (2009). Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity. Blood 113:3558-67.
157. Peeters P, Wlodarska I, Baens M, et al. (1997). Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders. Cancer Res 57:564-9. (Pubitemid 27085631)
158. Peterson LF, Boyapati A, Ahn EY, et al. (2007). Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood 110:799-805. (Pubitemid 47267414)
159. Plevin MJ, Zhang J, Guo C, et al. (2006). The acute myeloid leukemia fusion protein AML1-ETO targets E proteins via a paired amphipathic helix-like TBP-associated factor homology domain. Proc Natl Acad Sci USA 103:10242-7. (Pubitemid 44051151)
160. Prescott JD, Koto KS, Singh M, Gutierrez-hartmann A. (2004). The ETS transcription factor ESE-1 transforms MCF-12A human mammary epithelial cells via a novel cytoplasmic mechanism. Mol Cell Biol 24: 5548-64. (Pubitemid 38738185)
161. Prescott JD, Poczobutt JM, Tentler JJ, et al. (2011). Mapping of ESE-1 subdomains required to initiate mammary epithelial cell transformation via a cytoplasmic mechanism. Mol Cancer 10:103-17.
162. Riggi N, Stamenkovic I. (2007). The biology of Ewing sarcoma. Cancer Lett 254:1-10. (Pubitemid 47058800)
163. Robin TP, Smith A, Mckinsey E, et al. (2012). EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Mol Cancer Res 10: 1098-108.
164. Romana SP, Mauchauffe M, Le Coniat M, et al. (1995a). The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 85:3662-70.
165. Romana SP, Poirel H, Leconiat M, et al. (1995b). High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 86:4263-9.
166. Rostad K, Mannelqvist M, Halvorsen OJ, et al. (2007). ERG upregulation and related ETS transcription factors in prostate cancer. Int J Oncol 30:19-32.
167. Roudaia L, Cheney MD, Manuylova E, et al. (2009). CBFbeta is critical for AML1-ETO and TEL-AML1 activity. Blood 113:3070-9.
168. Rovigatti U, Watson DK, Yunis JJ. (1986). Amplification and rearrangement of Hu-ets-1 in leukemia and lymphoma with involvement of 11q23. Science 232:398-400. (Pubitemid 16047594)
169. Salomon-Nguyen F, Della-Valle V, Mauchauffe M, et al. (2000). The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion. Proc Natl Acad Sci USA 97: 6757-62. (Pubitemid 30412787)
170. Sasaki H, Kobayashi Y, Tanahashi M, et al. (2002). Ets-1 gene expression in patients with thymoma. Jpn J Thorac Cardiovasc Surg 50:503-7. (Pubitemid 38173524)
171. Sato Y, Abe M, Tanaka K, et al. (2000). Signal transduction and transcriptional regulation of angiogenesis. Adv Exp Med Biol 476: 109-15. (Pubitemid 32176130)
172. Schedin PJ, Eckel-mahan KL, Mcdaniel SM, et al. (2004). ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells. Oncogene 23:1766-79. (Pubitemid 38445168)
173. Scherr M, Battmer K, Winkler T, et al. (2003). Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 101:1566-9. (Pubitemid 36182535)
174. Schlottmann S, Erkizan HV, Barber-Rotenberg JS, et al. (2012). Acetylation increases EWS-FLI1 DNA binding and transcriptional activity. Front Oncol 2:1-12.
175. Schroeder A, Heller DA, Winslow MM, et al. (2012). Treating metastatic cancer with nanotechnology. Nat Rev Cancer 12:39-50.
176. Schwaller J, Parganas E, Wang D, et al. (2000). Stat5 is essential for the myelo-and lymphoproliferative disease induced by TEL/JAK2. Mol Cell 6:693-704.
177. Scotlandi K, Manara MC, Serra M, et al. (2011). Expression of insulinlike growth factor system components in Ewing's sarcoma and their association with survival. Eur J Cancer 47:1258-66.
178. Scott GK, Daniel JC, Xiong X, et al. (1994). Binding of an ETS-related protein within the DNase I hypersensitive site of the HER2/neu promoter in human breast cancer cells. J Biol Chem 269:19848-58. (Pubitemid 24250899)
179. Seidel JJ, Graves BJ. (2002). An ERK2 docking site in the Pointed domain distinguishes a subset of ETS transcription factors. Genes Dev 16:127-37. (Pubitemid 34049643)
180. Seth A, Watson DK. (2005). ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41:2462-78. (Pubitemid 41540623)
181. Shaikhibrahim Z, Lindstrot A, Langer B, et al. (2011). Differential expression of ETS family members in prostate cancer tissues and androgen-sensitive and insensitive prostate cancer cell lines. Int J Mol Med 28:89-93.
182. Sharrocks AD. (2002). Complexities in ETS-domain transcription factor function and regulation: lessons from the TCF (ternary complex factor) subfamily. The Colworth Medal Lecture. Biochem Soc Trans 30:1-9.
183. Shepherd TG, Kockeritz L, Szrajber MR, et al. (2001). The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis. Curr Biol 11:1739-48. (Pubitemid 33092162)
184. Shin S, Oh S, An S, Janknecht R. (2013). ETS variant 1 regulates matrix metalloproteinase-7 transcription in LNCaP prostate cancer cells. Oncol Rep 29:306-14.
185. Shore P, Whitmarsh AJ, Bhaskaran R, et al. (1996). Determinants of DNA-binding specificity of ETS-domain transcription factors. Mol Cell Biol 16:3338-49. (Pubitemid 26199853)
186. Siligan C, Ban J, Bachmaier R, et al. (2005). EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin. Oncogene 24:2512-24. (Pubitemid 40593042)
187. Slupsky CM, Gentile LN, Donaldson LW, et al. (1998). Structure of the Ets-1 pointed domain and mitogen-activated protein kinase phosphor-ylation site. Proc Natl Acad Sci USA 95:12129-34. (Pubitemid 28483730)
188. Stinson J, Inoue T, Yates P, et al. (2003). Regulation of TCF ETS-domain transcription factors by helix-loop-helix motifs. Nucleic Acids Res 31:4717-28. (Pubitemid 37441834)
189. Strahl T, Gille H, Shaw PE. (1996). Selective response of ternary complex factor Sap1a to different mitogen-activated protein kinase subgroups. Proc Natl Acad Sci USA 93:11563-8. (Pubitemid 26347161)
190. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. (2002). Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 277:18649-57. (Pubitemid 34952420)
191. Sun C, Dobi A, Mohamed A, et al. (2008). TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27:5348-53.
192. Sussan TE, Yang A, Li F, et al. (2008). Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome. Nature 451: 73-5.
193. Svensson S, Jirstrom K, Ryden L, et al. (2005). ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 24:4370-9. (Pubitemid 40961760)
194. Szymczyna BR, Arrowsmith CH. (2000). DNA binding specificity studies of four ETS proteins support an indirect read-out mechanism of protein-DNA recognition. J Biol Chem 275:28363-70.
195. Takai N, Miyazaki T, Nishida M, et al. (2003). The significance of Elf-1 expression in epithelial ovarian carcinoma. Int J Mol Med 12:349-54.
196. Tamir A, Howard J, Higgins RR, et al. (1999). Fli-1, an Ets-related transcription factor, regulates erythropoietin-induced erythroid proliferation and differentiation: evidence for direct transcriptional repression of the Rb gene during differentiation. Mol Cell Biol 19:4452-64. (Pubitemid 29242019)
197. Ter Haar WM, Meester-Smoor MA, Van Wely KH, et al. (2012a). The leukemia-associated fusion protein MN1-TEL blocks TEL-specific recognition sequences. PLoS One 7:26.
198. Ter Haar WM, Meester-Smoor MA, Van Wely KHM, et al. (2012b). The leukemia-associated fusion protein MN1-TEL blocks TEL-specific recognition sequences. PLoS One 7:e46085.
199. Tian J, Karin M. (1999). Stimulation of Elk1 transcriptional activity by mitogen-activated protein kinases is negatively regulated by protein phosphatase 2B (calcineurin). J Biol Chem 274:15173-80.
200. Tomlins SA, Laxman B, Varambally S, et al. (2008). Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10:177-88. (Pubitemid 351240884)
201. Tomlins SA, Palanisamy N, Brenner JC, et al. (2013). Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors. Am J Clin Pathol 139:771-9.
202. Tomlins SA, Rhodes DR, Perner S, et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-8. (Pubitemid 41528150)
203. Tootle TL, Rebay I. (2005). Post-translational modifications influence transcription factor activity: a view from the ETS superfamily. BioEssays 27:285-98. (Pubitemid 40476491)
204. Toretsky JA, Kalebic T, Blakesley V, et al. (1997). The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 272:30822-7. (Pubitemid 27527522)
205. Trimboli AJ, Cantemir-Stone CZ, Li F, et al. (2009). Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 461: 1084-91.
206. Turner DP, Findlay VJ, Moussa O, Watson DK. (2007). Defining ETS transcription regulatory networks and their contribution to breast cancer progression. J Cell Biochem 102:549-59. (Pubitemid 47557410)
207. Tynan JA, Wen F, Muller WJ, Oshima RG. (2005). Ets2-dependent microenvironmental support of mouse mammary tumors. Oncogene 24:6870-6. (Pubitemid 41509410)
208. Van den boorn JG, Schlee M, Coch C, Hartmann G. (2011). SiRNA delivery with exosome nanoparticles. Nat Biotechnol 29: 325-6.
209. Van Wely KH, Meester-Smoor MA, Janssen MJ, et al. (2007). The MN1-TEL myeloid leukemia-associated fusion protein has a dominant-negative effect on RAR-RXR-mediated transcription. Oncogene 26: 5733-40. (Pubitemid 47312816)
210. Van Wely KH, Molijn AC, Buijs A, et al. (2003). The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription. Oncogene 22:699-709. (Pubitemid 36269283)
211. Walker DM, Gonzales MS, Horita H, Gutierrez-Hartmann A. (2010). ESE-1 is required to maintain the transformed phenotype of MCF-7 and ZR-75-1 human breast cancer cells. Open Cancer J 3:77-88.
212. Wang CY, Petryniak B, Ho IC, et al. (1992). Evolutionarily conserved Ets family members display distinct DNA binding specificities. J Exp Med 175:1391-9.
213. Wang CY, Petryniak B, Thompson CB, et al. (1993). Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. Science 260:1330-5. (Pubitemid 23231978)
214. Wang J, Hoshino T, Redner RL, et al. (1998). ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 95:10860-5. (Pubitemid 28413159)
215. Wang Y, Wang L, Chen Y, et al. (2011). ER81 expression in breast cancers and hyperplasia. Patholog Res Int 2011:980513.
216. Wasylyk B, Hagman J, Gutierrez-hartmann A. (1998). Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem Sci 23:213-16. (Pubitemid 28302618)
217. Wasylyk C, Bradford AP, Gutierrez-Hartmann A, Wasylyk B. (1997). Conserved mechanisms of Ras regulation of evolutionary related transcription factors, Ets1 and Pointed P2. Oncogene 14:899-913. (Pubitemid 27122422)
218. Wasylyk C, Criqui-filipe P, Wasylyk B. (2005). Sumoylation of the net inhibitory domain (NID) is stimulated by PIAS1 and has a negative effect on the transcriptional activity of Net. Oncogene 24:820-8. (Pubitemid 40216090)
219. Wasylyk C, Kerckaert JP, Wasylyk B. (1992). A novel modulator domain of Ets transcription factors. Genes Dev 6:965-74.
220. Watson DK, Robinson L, Hodge DR, et al. (1997). FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements. Oncogene 14:213-21. (Pubitemid 27068307)
221. Wei GH, Badis G, Berger MF, et al. (2010). Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. Embo J 29: 2147-60.
222. Wheat W, Fitzsimmons D, Lennox H, et al. (1999). The highly conserved beta-hairpin of the paired DNA-binding domain is required for assembly of Pax-Ets ternary complexes. Mol Cell Biol 19:2231-41. (Pubitemid 29098281)
223. Wildonger J, Mann RS. (2005). The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor. Development 132: 2263-72. (Pubitemid 40872797)
224. Xia WY, Lien HC, Wang SC, et al. (2006). Expression of PEA3 and lack of correlation between PEA3 and HER-2/neu expression in breast cancer. Breast Cancer Res Treat 98:295-301.
225. Xu D, Dwyer J, Li H, et al. (2008). Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc. J Biol Chem 283:23567-80.
226. Yamada T, Abe M, Higashi T, et al. (2001). Lineage switch induced by overexpression of Ets family transcription factor PU.1 in murine erythroleukemia cells. Blood 97:2300-7. (Pubitemid 32291475)
227. Yan M, Burel SA, Peterson LF, et al. (2004). Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc Natl Acad Sci USA 101:17186-91. (Pubitemid 39627795)
228. Yan M, Kanbe E, Peterson LF, et al. (2006). A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemo-genesis. Nat Med 12:945-9. (Pubitemid 44175147)
229. Yang BS, Hauser CA, Henkel G, et al. (1996). Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol Cell Biol 16: 538-47. (Pubitemid 26029092)
230. Yang SH, Jaffray E, Hay RT, Sharrocks AD. (2003). Dynamic interplay of the SUMO and ERK pathways in regulating Elk-1 transcriptional activity. Mol Cell 12:63-74. (Pubitemid 36945037)
231. Yang SH, Shore P, Willingham N, et al. (1999). The mechanism of phosphorylation-inducible activation of the ETS-domain transcription factor Elk-1. Embo J 18:5666-74. (Pubitemid 29486384)
232. Yang SH, Vickers E, Brehm A, et al. (2001). Temporal recruitment of the mSin3A-histone deacetylase corepressor complex to the ETS domain transcription factor Elk-1. Mol Cell Biol 21:2802-14. (Pubitemid 32244924)
233. Yu J, Mani RS, Cao Q, et al. (2010). An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17:443-54.
234. Yu Z, Xia W, Wang HY, et al. (2006). Antitumor activity of an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1. Mol Carcinog 45:667-75. (Pubitemid 44406637)
235. Yuan Y, Zhou L, Miyamoto T, et al. (2001). AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 98: 10398-403. (Pubitemid 32803031)
236. Zelent A, Greaves M, Enver T. (2004). Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene 23:4275-83. (Pubitemid 38765136)
237. Zhang M, Maass N, Magit D, Sager R. (1997). Transactivation through Ets and Ap1 transcription sites determines the expression of the tumor-suppressing gene maspin. Cell Growth Differ 8:179-86. (Pubitemid 27068895)
238. Zou D, Yang X, Tan Y, et al. (2012). Regulation of the hematopoietic cell kinase (HCK) by PML/RARalpha and PU.1 in acute promyelo-cytic leukemia. Leuk Res 36:219-23.